Two articles touting Galena Biopharma were removed from the Seeking Alpha website Monday because they were written by the same person using different aliases, reports Adam Feuerstein of TheStreet.com
Feuerstein writes, “This is the second time Seeking Alpha has been forced to take action against individuals using multiple aliases to tout Galena, a small drug developer with a breast cancer vaccine in a phase III study. In January 2013, the investor Web site removed five articles promoting Galena written by the same individual under three different pseudonyms.
“The most recent incident is more serious and potentially damaging because of evidence linking Galena to a stock-promotions firm which wrote and published the articles on Seeking Alpha. The articles were part of a broader, coordinated ‘brand awareness campaign’ designed to boost Galena’s stock price, according to a document obtained by TheStreet.
“Aided by this promotional campaign, Galena shares tripled in value from this summer. Coincidence or not, Galena insiders have made millions of dollars by selling company stock in January.
“Galena did not respond to phone calls and emails seeking comment.”
Read more here.
Wall Street Journal reporter Ben Eisen has signed a contract with Norton to write a book about…
Reuters has hired Pia Krishnakutty as a news producer. She has been at The Print as a…
The Indianapolis Business Journal is looking for our next news editor, a role that focuses…
Axios has chosen Ben Berkowitz to be its next managing editor of business and markets.…
Business Insider editor in chief Jamie Heller sent out the following on Monday: I'm thrilled…
Rest of World editor in chief Anup Kaphle sent out the following on Monday: We are excited…
View Comments